



ASX ANNOUNCEMENT

Listing Rule 6.22.2 Adjustment to Option Exercise Prices

MELBOURNE, Australia 20 December 2024 – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) advises it has options on issue which, under Listing Rule 6.22.2 and their terms and conditions, require their exercise price to be adjusted as a consequence of the Entitlement Offer that closed on 9 October 2024 (**Entitlement Offer**).

Listing Rule 6.22 confers on an option the right to a change to its exercise price if there is a pro rata issue (except a bonus issue). The reduction in exercise price to be applied is outlined in the formula in Listing Rule 6.22.2.

As a result of the Entitlement Offer, applying the formula in Listing Rule 6.22.2 requires a reduction in the exercise price of issued options of \$0.0013 per option.

In accordance with Listing Rule 3.11.2, Lumos advises that, effective from 31 December 2024, the exercise price of the following options will be amended in accordance with their terms and conditions and the Listing Rules:

ASX Code	No. Options	Option expiry date	Current exercise price	New exercise price
LDXAS	100,000	30 January 2028	\$0.0313	\$0.0300
LDXAG	1,250,304	30 June 2025	\$1.2500	\$1.2487
LDXAL	5,241,500	26 August 2027	\$0.0589	\$0.0576
LDXAK	7,500,000	18 July 2029	\$0.3000	\$0.2987
LDXAM	1,665,026	31 August 2026	\$0.0589	\$0.0576
LDXAN	1,250,000	31 August 2027	\$0.0589	\$0.0576
LDXAO	15,000	28 February 2026	\$0.0589	\$0.0576
LDXAP	1,013,972	11 December 2027	\$0.0474	\$0.0461
LDXAR	41,666,668	08 January 2027	\$0.0720	\$0.0707
LDXAT	10,100,000	08 May 2028	\$0.0243	\$0.0230
LDXAU	3,750,000	10 August 2028	\$0.0138	\$0.0125
LDXAV	5,610,000	18 January 2029	\$0.0700	\$0.0687

The effect of the change in exercise prices is a reduction of \$103,963 in the amount of capital that would be raised by the Company should all the above options be exercised.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Lumos - Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Lumos - Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Lumos - Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598